{
    "2021-07-13": [
        [
            {
                "time": "2023-10-01",
                "original_text": "药明康德是如何\"逆袭\"的？",
                "features": {
                    "keywords": [
                        "药明康德",
                        "逆袭"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "睿智医药乱象丛生 盈利能力低下 增速远逊同行",
                "features": {
                    "keywords": [
                        "睿智医药",
                        "乱象",
                        "盈利能力",
                        "增速"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "CRO淘金赛道“领跌者” 泰格医药转型“投资家”AB面",
                "features": {
                    "keywords": [
                        "CRO",
                        "泰格医药",
                        "领跌",
                        "转型",
                        "投资家"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "2021年医药生物中期策略报告：需求长期景气 布局创新、医疗服务和消费主线",
                "features": {
                    "keywords": [
                        "医药生物",
                        "需求",
                        "景气",
                        "创新",
                        "医疗服务",
                        "消费"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "豪掷98亿！泰格医药大手笔设产业基金",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "产业基金",
                        "投资"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "人类基因组编辑要如何监管？世卫组织今日发布最新推荐",
                "features": {
                    "keywords": [
                        "人类基因组",
                        "编辑",
                        "监管",
                        "世卫组织"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "CRISPR基因编辑敲除PD-1，“改良版”即用型CAR-T疗法进入临床试验",
                "features": {
                    "keywords": [
                        "CRISPR",
                        "基因编辑",
                        "PD-1",
                        "CAR-T",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "降低疾病进展风险37%，杨森CD38抗体组合获批二线治疗多发性骨髓瘤",
                "features": {
                    "keywords": [
                        "杨森",
                        "CD38",
                        "抗体",
                        "多发性骨髓瘤"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "药明康德：因零息可转换债券获转换，发行139.88万股",
                "features": {
                    "keywords": [
                        "药明康德",
                        "可转换债券",
                        "发行"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "因零息可转换债券获转换 药明康德(02359)发行139.88万股A股",
                "features": {
                    "keywords": [
                        "药明康德",
                        "可转换债券",
                        "发行"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "药明康德：因期权获行使，发行13.405万股A股",
                "features": {
                    "keywords": [
                        "药明康德",
                        "期权",
                        "发行"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "因期权获行使 药明康德(02359)发行13.405万股A股",
                "features": {
                    "keywords": [
                        "药明康德",
                        "期权",
                        "发行"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}